FDAnews
www.fdanews.com/articles/131373-celator-completes-enrollment-in-a-second-phase-ii-trial-of-cpx-35

Celator Completes Enrollment in a Second Phase II Trial of CPX-35

October 26, 2010
Celator Pharmaceuticals Tuesday announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia in first relapse.
heraldonline